Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC/AHA) 2018 guideline for cholesterol management
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0283369 ↗Kurz gefasst
Leitlinie in der Zeitschrift PLOS ONE, 2023. Verfasst von Mohammad M AlAhmad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, College of Pharmacy, Al Ain University, Al Ain, United Arab Emirates. Hauptthemen laut MEDLINE: Hypercholesterolemia, Cardiovascular Diseases, Cardiology, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
The study aims to examine the extent to which the updated ACC/AHA management of blood cholesterol guideline (2018) is implemented in practice and to assess the value of the clinical pharmacist interventions in improving physicians’ adherence the guidelines recommendations.
Methods
We utilized in this study an interventional before-after design. The study was conducted on 272 adult patients who visited the study site internal medicine clinics and were candidates for statin therapy based on the 2018 ACC/AHA guidelines for cholesterol management. Adherence to guideline recommendations was measured before and after clinical pharmacists’ interventions by calculating the percentage of patients receiving statin therapy as per guideline recommendation, the type and intensity (moderate or high intensity) of statin therapy used, and the need for additional non-statin therapy.
Results
Adherence with guideline recommendations was significantly improved from 60.3% to 92.6% (X2 = 79.1, p = 0.0001) after clinical pharmacist interventions. Among patients who were on statin therapy, the percentage of those who were on proper statin intensity increased significantly from 47.6% to 94.4% (X2 = 72.5, p = 0.0001). The combination of statins with non-statin therapies such as ezetimibe and PCSK9 inhibitors increased from 8.5% to 30.6% (X2 = 95, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, College of Pharmacy, Al Ain University, Al Ain, United Arab Emirates.
- AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab Emirates.
- Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
- Mediclinic AlAin Hospital, Al Ain, United Arab Emirates.
- Czech Rehabilitation Hospital, Al Ain, United Arab Emirates.
- Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, University of Jordan, Amman, Jordan.
ORCID-Profile: Mohammad M AlAhmad
Zitieren
APA
AlAhmad, M. M., ZainAlAbdin, S., AlAhmad, K., AlAhmad, I., & AbuRuz, S. (2023). Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC/AHA) 2018 guideline for cholesterol management. PLOS ONE. https://doi.org/10.1371/journal.pone.0283369
Vancouver
AlAhmad MM, ZainAlAbdin S, AlAhmad K, AlAhmad I, AbuRuz S. Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC/AHA) 2018 guideline for cholesterol management. PLOS ONE. 2023. doi:10.1371/journal.pone.0283369
BibTeX
@article{AlAhmad2023,
author = {AlAhmad, Mohammad M and ZainAlAbdin, Sham and AlAhmad, Khozama and AlAhmad, Iqbal and AbuRuz, Salah},
title = {Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC/AHA) 2018 guideline for cholesterol management},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0283369}
}
EUVIMED